Herbert A. Fritsche, Ph.D.
Dr. Herbert Fritsche is a native of Houston, Texas where he received his early education and B.S. degree in Chemistry from the University of Houston in 1963. He received an M.S. degree (1965) and Ph.D. degree (1968) in Chemistry from Texas A & M University. From 1967 to 1969, he served on active military duty as Captain and as Assistant Chief, Clinical Chemistry at the First U.S. Army Medical Laboratory in Ft. Meade, MD. In 1969, he accepted the position as Chief of Clinical Chemistry at M. D. Anderson Cancer Center and has served in that capacity for the past 38 years. In that capacity, Dr. Fritsche directs the clinical chemistry testing operations for the MD Anderson Hospital and outpatient clinics; participates in the education of medical fellows, pathology residents, graduate students and medical technology students; and conducts an active research program in the development and validation of cancer diagnostics. He has served in all elected positions in the Texas Section of the American Association for Clinical Chemistry (AACC), and he has served on and chaired the National Education Committee and the Education Committee of the Immunology Division of the AACC. He has served on many of the committees of the AACC and the NACB, and numerous review committees for the National Cancer Institute. He served as National President of the Clinical Ligand Assay Society, and the Texas Medical Center Chapter of Sigma Xi. Currently, he is a member of the editorial board of six journals, a Fellow in the National Academy of Clinical Biochemistry (NACB), a member of the Tumor Marker Expert Panel (American Society of Clinical Oncology), the Tumor Marker Guidelines Committee for (NACB), the Technology Expert Panel for Blue Cross Blue Shield, and he is an active member of five professional societies. He is the recipient of the 1979 Outstanding Clinical Chemist Award from the Texas Section-AACC, the 1992 National AACC Award for Outstanding Contributions in Education, the 1997 Johnson and Johnson Award for Outstanding Research from the NACB, the CLAS Distinguished Scientist Award in 1999 and the 2006 Morton K. Schwartz AACC Award for Significant Contributions in Cancer Research Diagnostics. He has lectured at many international meetings and has published more than 180 manuscripts and 30 book chapters in the field of cancer diagnostics. He is a member of the scientific advisory boards for seven companies, he holds four patents and two patent applications, is the co-author of a textbook on Tumor Markers, published by AACC press, and he is the Meeting Director of a Biennial Conference on Cancer Diagnostics sponsored by the M. D. Anderson Cancer Center.